Long term survival in diffuse infiltrative brainstem gliomas in children and adolescents treated with radiatherapy and Nimotuzumab

J. Alert, I. Chon, J. Valdes, R. Ropero, J. Reno, Migdalia Perez, M. Forteza, Débora García
{"title":"Long term survival in diffuse infiltrative brainstem gliomas in children and adolescents treated with radiatherapy and Nimotuzumab","authors":"J. Alert, I. Chon, J. Valdes, R. Ropero, J. Reno, Migdalia Perez, M. Forteza, Débora García","doi":"10.15406/IJRRT.2018.05.00176","DOIUrl":null,"url":null,"abstract":"Background Brainstem gliomas have a short survival time chemotherapy has not improved outcome We report the result obtained with the combination of Radiotherapy and the monoclonal antibody Nimotuzumab in a series of these tumors Material and methods children and adolescents treated with irradiation and Nimotuzumab were included between Jan and December all with the diagnosis of diffuse infiltrative pontine gliomas DIPG irradiated at the Instituto Nacional de Oncologia y Radiobiologia in Havana Cuba Nimotuzumab was applied during the period receiving Radiotherapy and them monthly for one year or more Results Median age at diagnosis was years range years old median survival was months and Kaplan Meier survival was at years and at years established till years Addition of Nimotuzumab was safe and well tolerated Conclusion Combination of Nimotuzumab and Radiotherapy is safe and could increase survival","PeriodicalId":214028,"journal":{"name":"International Journal of Radiology & Radiation Therapy","volume":"77 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiology & Radiation Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/IJRRT.2018.05.00176","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background Brainstem gliomas have a short survival time chemotherapy has not improved outcome We report the result obtained with the combination of Radiotherapy and the monoclonal antibody Nimotuzumab in a series of these tumors Material and methods children and adolescents treated with irradiation and Nimotuzumab were included between Jan and December all with the diagnosis of diffuse infiltrative pontine gliomas DIPG irradiated at the Instituto Nacional de Oncologia y Radiobiologia in Havana Cuba Nimotuzumab was applied during the period receiving Radiotherapy and them monthly for one year or more Results Median age at diagnosis was years range years old median survival was months and Kaplan Meier survival was at years and at years established till years Addition of Nimotuzumab was safe and well tolerated Conclusion Combination of Nimotuzumab and Radiotherapy is safe and could increase survival
放疗和尼莫单抗治疗儿童和青少年弥漫性浸润性脑干胶质瘤的长期生存率
背景:脑干胶质瘤生存时间短,化疗并没有改善预后。我们报告了放疗和单克隆抗体尼莫单抗联合治疗一系列此类肿瘤的结果。材料和方法:在1月至12月期间,在哈瓦那国家肿瘤放射生物学研究所接受放疗和尼莫单抗治疗的儿童和青少年均被诊断为弥漫性浸润性脑桥胶质瘤结果诊断时中位年龄为年,年龄中位生存期为月,Kaplan Meier生存期为年,建立至年。添加尼莫单抗是安全的,耐受性良好结论尼莫单抗与放疗联合使用是安全的,可提高生存率
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信